P192  Secukinumab provides rapid and sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 2-year results from the Phase 3 FUTURE 5 study

Conclusion Secukinumab provided rapid improvements in TJC and SJC at Week 16, which were sustained through Week 104, irrespective of TNFi history/concomitant MTX use. P192 Table 1:Selected baseline characteristics and 78 TJC and 76 SJC Results at Week 104Selected baseline characteristicsVariableSEC 300 mg (N = 222)SEC 150 mg (N = 220)SEC 150 mgno LD (N = 222)PBO (N = 332)Mean adjusted 78 TJC scoreTotal population19.821.221.821.2Mean adjusted 76 SJC scoreTotal population10.012.111.911.778 TJC and 76 SJC Results at Week 104EndpointSECPBO-SEC300 mg SC(N = 100)150 mg SCaa(N = 100)150 mg SCno LDbb(N = 222)300 mg SC (N = 153)150 mgcc (N = 153)Adjusted 78 TJC (total population)Change from baseline (SD)-15.4 (12.5)-16.6 (14.3)-17.7 (15.3)-17.2 (14.9)-15.2 (13.0)Adjusted 76 SJC (total population)Change from baseline (SD)-8.7 (7.3)-10.3 (10.5)-10.6 (9.6)-10.7 (10.0)-9.6 (9.2)Adjusted 78 TJC (TNF status)TNFi-naiveChange from baseline (SD)-14.1 (11.6)-15.7 (14.1)-17.7 (15.0)-16.6 (13.7)-14.5 (12.6)TNFi-IRChange from baseline (SD)-19.0 (14.3)-19.1 (14.7)-17.9 (16.3)-18.9 (18.1)-17.6 (14.5)Adjusted 76 SJC (TNF status)TNFi-naiveChange from baseline (SD)-8.6 (7.2)-9.6 (9.6)-10.9 (10.1)-10.5 (8.6)-9.2 (7.5)TNFi-IRChange from baseline (SD)-9.1 (7.8)-12.2 (12.8)-9.9 (7.9)-11.0 (13.4)-10.9 (13.4)Adjusted 78 TJC (MTX use)Concomitant MTX useChange from baseline (SD)-15.7 (12.3)-16.4 (14.7)-17.0 (14.0)-17.8 (16.0)-15.8 (14.2)No concomitant MTX useChange from baseline (SD)-15.1 (12.8)-16.8 (13.9...
Source: Rheumatology - Category: Rheumatology Source Type: research